Table 3. Indicators of the oxidant-antioxidant system in urine in patients with acute pyelonephritis in different trimesters of pregnancy before and after treatment (M±m)
Indicators |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
Healthy non-pregnant n=20 |
Non-pregnant women with acute pyelonephritis n=20 |
Pregnant women with acute pyelonephritis |
||||||||
1st trimester |
2nd trimester |
3 trimester |
||||||||
before treatment |
basic treatment |
before treatment |
basic treatment |
basic treatment + Viferon n=15 |
before treatment |
basic treatment |
basic treatment + Viferon n=15 |
|||
n=15 |
n=15
|
n=15
|
||||||||
malondialdehyde, µmol/l |
0.3±0.02 |
0.5±0.03*1 |
0.67±0.04*1,2 |
0.45±0.03*1,3 |
1.9±0.1*1,2 |
0.86±0.08*1,5 |
0.64±0.04*1,5,6 |
2.1±0.2*1-3 |
0.72±0.08*1,,8 |
0.49±0.04*1,8,9 |
acylhydroperoxide, conventional units |
0.12±0.01 |
0.22±0.02*1 |
0.29±0.02*1,2 |
0.14±0.02*3 |
1.1±0.04*1,2 |
0.47±0.02*1,5 |
0.24±0.01*1,5,6 |
0.97±0.06*1-3 |
0.29±0.03*1,8 |
0.14±0.02*8,9 |
superoxide dismutase, conventional units |
3.4±0.3 |
7.4±0.2*1 |
7.9±0.3*1 |
8.8±0.4*1,3 |
9.0±0.8*1-3 |
6.6±0.3*1,5 |
6.5±0.2*1,5 |
9.9±1.2*1-3 |
10.6±0.7*1 |
15.4±1.4*1,8,9 |
Catalase, U/mL |
0.49±0.05 |
0.74±0.08*1 |
0.85±0.07*1 |
0.79±0.08*1 |
0.8±0.08*1 |
0.71±0.048*1 |
0.73±0.048*1 |
0.85±0.07*1 |
0.82±0.01*1 |
0.89±0.02*1 |
Neopterin, nmol/l |
2.1±0.2 |
3.2±0.2*1 |
3.9±0.2*1,2 |
2.6±0.1*1,3 |
4.3±0.1*1-3 |
3.7±0.08*1,5 |
2.3±0.12*5,6 |
4.6±0.2*1-3 |
2±0.08*8 |
1.9±0.1*8 |
СМNO, mmol/l |
0.28±0.02 |
1.2±0.1*1 |
1.5±0.07*1,2 |
0.89±0.08*1,3 |
2.4±0.2*1-3 |
1.4±0.1*1,5 |
0.72±0.02*1,5,6 |
2.1±0.1*1-3 |
1.6±0.2*1,8 |
0.9±0.02*1,8,9 |